复发或不耐药的中枢神经系统淋巴瘤成功地通过glofitamab与lenalidomide结合治疗
Yin-Yin Peng1, Xiao-Qiong Tang1
1Department of Hematology Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Frontiers in oncology
|November 19, 2025
概括
格洛菲他马布和莱纳利多米德的组合显示出对治疗复发性/难治性中枢神经系统淋巴瘤 (CNSL) 的希望. 这种新的治疗方案在一小群耐受性良好的患者中实现了100%的反应率.
科学领域:
- 神经瘤学神经瘤学
- 血液学 血液学 血液学
- 临床药理学 临床药理学
背景情况:
- 中枢神经系统淋巴瘤 (CNSL) 是一种罕见且具有高复发率和死亡率的侵袭性恶性瘤.
- 目前,对于复发性/耐药性 (R/R) CNSL 没有标准治疗方法,这突出了未满足的临床需求.
- 有效的救援疗法对于改善R/R CNSL患者的治疗结果至关重要.
研究的目的:
- 评价R/R CNSL患者用格洛菲他马布与列纳利多米德联合的疗效和安全性.
- 用成像和细胞学来评估治疗反应.
- 探索这种具有挑战性的疾病的潜在新治疗方案.
主要方法:
- 在2024年10月至2025年6月期间接受治疗的4名R/R CNSL患者的回顾性分析.
- 治疗包括glofitamab加上莱纳利多米德.
- 通过脑MRI和每两周期一次的CSF细胞学来评估反应.
主要成果:
- 所有4名患者在2个周期 (2CRu,2PR) 后都实现了快速缓解,导致100%的整体应答率.
- 在4个周期 (3CR/CRu,1PR) 后观察到深度缓解.
- 该组合表现出极好的耐受性,没有3级以上的血液毒性,细胞因子释放综合征,神经毒性或器官功能障碍. 没有因不良事件而停止治疗.
结论:
- 格罗菲他马布-莱纳利多米德组合在R/R CNSL中表现出有前途的抗瘤活性.
- 这种疗法似乎被很好地容忍,这表明它有可能成为一种有效的救援疗法.
- 需要在更大的试验中进行进一步的调查来证实这些发现.
相关概念视频
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
465
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
465
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
417
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
417
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
469
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
469
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K


